Share this article
Share this article
ResearchAndMarkets.com s offering.
The European pharmaceutical CRO market accounted for $11.96 billion in 2019 and will grow by 7.9% annually over 2020-2030 owing to the rising incidence of disease, rising healthcare expenditures, increasing dependence on contract research organizations due to improved efficiency and productivity.
Highlighted with 36 tables and 45 figures, this report is based on comprehensive research of the entire Europe pharmaceutical CRO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies of the period 2015-2019 and provides a forecast from 2020 till 2030 with 2019 as the base year.
/PRNewswire/ TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients.
Precision Optics Reports Second Quarter Fiscal Year 2021 Financial Results
Conference Call Scheduled for today, February 16, 2021 at 5:00pm ET
News provided by
Share this article
Share this article
GARDNER, Mass., Feb. 16, 2021 /PRNewswire/ Precision Optics Corporation, Inc. (OTCQB: PEYE), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its second quarter fiscal year ended December 31, 2020.
Second quarter fiscal 2021 highlights:
Revenue for the quarter ended December 31, 2020 was $2.79 million compared to $2.80 million in the same quarter of the previous fiscal year, essentially flat year over year; and up slightly sequentially compared to $2.76 million in the quarter ended September 30, 2020.
Exact Sciences Announces Fourth Quarter 2020 Results
News provided by
Share this article
Share this article
MADISON, Wis., Feb. 16, 2021 /PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020. Exact Sciences finished another transformative year by delivering strong fourth quarter results against a challenging backdrop because of the pandemic, said Kevin Conroy, chairman and CEO of Exact Sciences. We are a leader in cancer diagnostics because of our people, scientific platform, and market-leading Cologuard and Oncotype tests. We aim to extend this leadership throughout the cancer continuum and bring additional tests to patients to help improve cancer outcomes.
/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for.